Clinical trial NCT02049814: Efficacy and Safety of Voglibose Compared With Acarbose in Participants With Type 2 Diabetes
Official title: A Randomized, Open-label, Non-inferiority Study to Compare the Efficacy and Safety of Voglibose and Acarbose in Patients With Type 2 Diabetes Mellitus With Poor Control of Metformin
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE4
Conditions: Type 2 Diabetes Mellitus
Keywords: Drug therapy
Lead sponsor: Takeda
Sponsor class: INDUSTRY
First posted: 2014-01-30
Enrollment: 494
Sex: ALL
Minimum age (years): 18
Maximum age (years): 75
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The primary purpose of this study is to evaluate the efficacy of voglibose versus acarbose combined with metformin in participants with type 2 diabetes mellitus (T2DM) by evaluating levels of glycosylated hemoglobin.

Detailed description: The drug being tested in this study is called voglibose. Voglibose is being tested to treat type 2 diabetes in people who have diabetes that is inadequately controlled on metformin alone. This study will look at glycemic control in people who take voglibose.

The study will enroll 494 patients. All participants will be enrolled in a 2-week screening phase and a metformin run-in phase. Eligible participants will be randomly assigned (by chance, like flipping a coin) to one of the two treatment groups:

* Metformin and Voglibose 0.2 mg
* Metformin and Acarbose 50 mg

All participants will be asked to take their current dose of metformin tablets and either voglibose or acarbose tablets three times a day throughout the study.

This multi-center trial will be conducted in China. The overall time to participate in this study is up to 20 weeks and participants will make 8 visits to the clinic.

Eligibility criteria: Inclusion Criteria:

1. Has a historical diagnosis of type 2 diabetes mellitus (T2DM) for at least 6 months prior to the screening visit (V1).
2. Is male or female and aged from 18 to 75 years, inclusively.
3. Has a body mass index (BMI) between 20 and 45 kg/m\^2, inclusively.
4. Is experiencing inadequate glycemic control with a glycosylated hemoglobin (HbA1c) concentration between 7.0% and 10.0%, inclusively.
5. Has been treated with Metformin for at least 3 months and at a stable dose (≥1000 mg/day) for at least 8 weeks prior to Screening, unless there is documentation that the participant's current dose is his or her maximum tolerated dose (MTD) and MTD is ≤1000 mg/day.
6. Keeps constant body weight with fluctuation range no more than 10% over for at least 3 months before screening.
7. Hemoglobin levels of the participant are ≥12 g/dL (≥120 g/L) in male and≥ 10 g/dL (≥100 g/L) in female at screening visit.
8. Male serum creatinine \<1.5 mg/dL and female serum creatinine \<1.4 mg/dL, or estimated glomerular filtration rate (eGFR) \>60 ml/min/1.73m\^2 based on calculation using the Modification of Diet in Renal Disease (MDRD) approximation at Screening.
9. In the opinion of the investigator, the participant is capable of understanding and complying with protocol requirements.
10. The participant or, when applicable, the participant's legally acceptable representative signs and dates a written informed consent form and any required privacy authorization prior to the initiation of any study procedures.

Exclusion Criteria:

1. Type 1 diabetes mellitus.
2. Has received insulin, voglibose, acarbose or other oral hypoglycemic drugs (except Metformin) for accumulative total of more than 7 days within the latest 3 months prior to Visit 1.
3. Has a history of cardiovascular disease: acute myocardial infarction, class III or IV heart failure, or cerebrovascular accident (stroke) within the latest 3 months prior to Visit 1.
4. The participant's liver function is damaged and has a significant clinical sign or symptom of hepatopathy, acute or chronic hepatitis, or the value of alanine aminotransferase (ALT) or aspartate aminotransferase (AST) is 3 times more than the upper limit of normal level at Visit 1.
5. Has an active proliferative retinopathy or macular degeneration that need to have an urgent treatment in the opinion of investigators.
6. Has a frequent attack of hypoglycemia or loses consciousness due to hypoglycemia in the opinion of investigators.
7. Has one or more times ketoacidosis or hyperosmotic status/coma.
8. Is receiving long-term (\>14days) systemic glucocorticoid treatment (except the medicine: local, intraocular, inhalation or via the nose) or has received such treatment for 4 weeks at Visit 1.
9. Has a hematopathy (e.g. hemolytic anemia, drepanocytosis) that may interfere with the HbA1c test.
10. Has other liabilities (e.g. drug abuse, alcoholism or mental disorder) that may hinder the participant to follow and complete the study.
11. Has participated in another clinical study within the past 90 days or has received any investigational compound within 30 days prior to randomization.
12. Is unsuitable for this study in the opinion of investigators.
13. Has a disease need to use other taboo or caution drugs that is not listed in this study.
14. If female, is pregnant or lactating or intending to become pregnant before, during, or within 30 days after participating in this study.

Primary outcomes:
measure: Change From Baseline in Glycosylated Hemoglobin (HbA1c) at Week 12
timeFrame: Baseline, Week 12
Secondary outcomes:
measure: Change From Baseline in HbA1c at Week 6
timeFrame: Baseline and Week 6
measure: Change From Baseline in Fasting Blood Glucose Over Time
timeFrame: Baseline, Weeks 6 and 12
measure: Change From Baseline in Postprandial Plasma Glucose (PPG) Over Time
timeFrame: 1 and 2 hours after meal at Baseline, Weeks 6 and 12
measure: Change From Baseline in Fasting Insulin at Week 12
timeFrame: Baseline, Week 12
measure: Change From Baseline in Postprandial Serum Insulin at Week 12
timeFrame: 1 and 2 hours after meal at Baseline and Week 12
measure: Change From Baseline in Fasting Glucagon at Week 12
timeFrame: Baseline, Week 12
measure: Change From Baseline in Postprandial Serum Glucagon at Week 12
timeFrame: 1 and 2 hours after meal at Baseline and Week 12
measure: Change From Baseline in Calculated Homeostatic Model Assessment Insulin Resistance (HOMA IR) at Week 12
timeFrame: Baseline, Week 12
measure: Change From Baseline in Insulin Homeostatic Model Assessment Beta Cell Function (HOMA β) at Week 12
timeFrame: Baseline, Week 12
measure: Change From Baseline in Body Weight Over Time
timeFrame: Baseline, Weeks 2, 6 and 12
Other outcomes:
Locations:
city: Hefei
country: China
state: Anhui
city: Maanshan
country: China
state: Anhui
city: Beijing
country: China
state: Beijing
city: Guangzhou
country: China
state: Guangdong
city: Shenzhen
country: China
state: Guangdong
city: Taishan
country: China
state: Guangdong
city: Zhuzhou
country: China
state: Hunan
city: Nanjing
country: China
state: Jiangsu
city: Xuzhou
country: China
state: Jiangsu
city: Changchun
country: China
state: Jilin
city: Jilin
country: China
state: Jilin
city: Shenyang
country: China
state: Liaoning
city: Qingdao
country: China
state: Shandong
city: Shanghai
country: China
state: Shanghai
city: Yan An
country: China
state: Shanxi
city: Yanan
country: China
state: Shanxi
city: Tianjin
country: China
state: Tianjin
city: Wenzhou
country: China
state: Zhejiang
Study officials:
affiliation: Takeda
name: Medical Director, Clinical Science
role: STUDY_DIRECTOR
References: